You are here: Industry Insights > AZD1222

News List

Pharmaceutical News of August | PharmaSources.com: COVID-19 PharmaSources/Caicai
September 23, 2020
AstraZeneca announced the initiation of Phase III clinical trial for its adenovirus vector-based COVID-19 vaccine: AZD1222 in the U.S. on Aug. 31, which has a code of D8110C00001 and is funded by the Biomedical Advanced Research and Development Authority
AstraZeneca COVID-19 Vaccine Confirms 100% Protection Against Severe Disease in Phase III Trials americanpharmaceuticalreview
February 08, 2021
The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no ...
HALIX to Provide Large-Scale GMP Manufacture of COVID-19 Vaccine americanpharmaceuticalreview
December 24, 2020
HALIX has signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.
AstraZeneca says its vaccine should be effective against new coronavirus variant expresspharma
December 24, 2020
British drugmaker AstraZeneca told Reuters on Tuesday its COVID-19 vaccine should be effective against the new coronavirus variant, adding that studies were under way to fully probe the impact of the mutation.
AstraZeneca to test combination of AZD1222 and Sputnik V vaccines europeanpharmaceuticalreview
December 15, 2020
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.
AstraZeneca’s vaccine shows efficacy in preventing symptomatic Covid-19 pharmaceutical-technology
December 10, 2020
AstraZeneca has reported that interim analysis from the Phase III programme of the Covid-19 vaccine, AZD1222, showed it is safe and effective at preventing symptomatic Covid-19.
HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact contractpharma
December 09, 2020
HALIX to provide large-scale GMP manufacture of AZD1222 at its cGMP facility in the Netherlands.
AstraZeneca likely to conduct new global low-dose Covid-19 vaccine trial pharmaceutical-technology
November 30, 2020
AstraZeneca may initiate an additional global trial to evaluate the efficacy of its Covid-19 vaccine candidate, AZD1222, using a lower dosage.
AstraZeneca COVID-19 Vaccine Meets Primary Efficacy Endpoint americanpharmaceuticalreview
November 25, 2020
Positive high-level results from an interim analysis of clinical trials of AstraZeneca’s COVID-19 vaccine, AZD1222, in the UK and Brazil showed the vaccine was highly effective in preventing Coronavirus.
AZ/Oxford University’s COVID-19 vaccine shows average efficacy of 70% pharmatimes
November 24, 2020
AstraZeneca (AZ) and Oxford University’s COVID-19 vaccine candidate AZD1222 has scored an average efficacy rate of 70% in an interim analysis of phase II/III trials conducted in the UK and Brazil.

Previous page 1 2 3 4 Next page